Recent research indicates that Clostridium butyricum MIYAIRI 588 (CBM588), a probiotic, may enhance immune responses in cancer patients, particularly those undergoing immune checkpoint inhibitor therapy. The findings suggest that patients receiving this probiotic could experience improved response rates and overall survival.
CBM588 has a long history of use in Japan, dating back to the 1960s, primarily for treating gastrointestinal disturbances. Its established safety record includes applications in young children and during pregnancy, making it a promising candidate for further research in oncology.
In the study, researchers identified a specific immune cell population, Vγ9Vδ2 T-cells, activated by CBM588. Notably, higher activation of these T-cells in lung cancer patients correlated with better treatment outcomes, indicating a potential mechanism through which the probiotic may exert its effects.
Dr. Garry Dolton noted, “Several recent studies have shown that the gut microbiome is linked to how well patients respond to checkpoint blockade therapy,” emphasizing the growing interest in the relationship between gut health and cancer treatment efficacy.
Professor Chihiro Motozono from Kumamoto University remarked, “Our colleagues in Kumamoto observed encouraging clinical results with CBM588, but the key question was how it was benefiting patients.” This highlights the need for further investigation into the biological mechanisms at play.
Professor Andrew Sewell added, “This study moves us from an association between the gut microbiome and cancer treatment outcomes to a defined immune pathway,” suggesting a significant advancement in understanding how probiotics may influence cancer therapy.
The research was supported by various institutions, including Cardiff University, Kumamoto University, AMED Research Programs, the Wellcome Trust, and Cancer Research Wales. However, details remain unconfirmed regarding the exact biological mechanisms through which CBM588 affects immune responses.
Furthermore, the clinical analyses conducted to date have been modest in size, indicating that further prospective trials are necessary to validate these findings and explore the full potential of CBM588 in cancer immunotherapy.